Adult Rhabdomyosarcoma: Clinical Features and Radiotherapy Outcomes—The Turkish Oncology Group (TOG) Bone and Soft Tissue Sarcoma Study Group

Basit Öğe Kaydı
dc.contributor.authorKıraklı, Esra Korkmaz
dc.contributor.authorİribaş, Ayça
dc.contributor.authorErgen, Arzu
dc.contributor.authorAtalar, Banu
dc.contributor.authorAğaoğlu, Fulya
dc.contributor.authorDınçbaş, Fazilet Önder
dc.contributor.authorAnacak, Yavuz
dc.date.accessioned2020-12-01T12:33:08Z
dc.date.available2020-12-01T12:33:08Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractOBJECTIVE Although rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma diagnosed in childhood, it represents only 2%–5% of adult soft tissue sarcomas. the aim of the present study was to better understand the clinical characteristics, treatment approaches, and outcomes of patients with adult RMS who received radiotherapy (RT) as a component of their multidisciplinary management since there are scarce data on adult RMS due to its rarity. METHODS the medical records of patients with adult RMS who were ?18 years old and treated with RT between January 1995 and August 2016 in four different radiation centers were evaluated in terms of clinical characteristics, treatment, and follow-up data retrospectively. RESULTS There were 28 patients. the median age at diagnosis was 28 (19–53) years. the most common site of involvement was the head and neck (25%), and parameningeal region involvement was prominent (92%) among them. in general, unfavorable site of involvement was markedly higher than favorable ones (82% vs. 18%). Alveolar and pleomorphic subtypes compromised 75% of the cases. Fifteen patients had surgery, 26 chemotherapy, 10 radical intent of RT, 9 adjuvant, 3 preoperative, and 6 palliative. the follow-up time was from 3 to 235 (median 18) months, disease-free survival was between 2 and 48 (median 12) months, and 5-year overall survival (OS) was 25% (median OS 20 (4–235) months). There were significant differences in terms of survival according to histopathological subtypes (p: 0.017), risk groups (p<0.001), Intergroup Rhabdomyosarcoma Study Group (IRSG) grouping and IRSG staging (p<0.001). CONCLUSION Adult RMS has unfavorable clinical presentation and worse outcome compared with pediatric RMS. Histopathological subtype and risk grouping to define the prognosis used in pediatric cases also might be valid in adult RMS.en_US
dc.identifier.endpage135en_US
dc.identifier.issn1300-7467
dc.identifier.issue4en_US
dc.identifier.startpage129en_US
dc.identifier.urihttps://app.trdizin.gov.tr//makale/TXpVek5EWTFOUT09
dc.identifier.urihttps://hdl.handle.net/11454/66462
dc.identifier.volume33en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofTürk Onkoloji Dergisien_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject0-Belirleneceken_US
dc.titleAdult Rhabdomyosarcoma: Clinical Features and Radiotherapy Outcomes—The Turkish Oncology Group (TOG) Bone and Soft Tissue Sarcoma Study Groupen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu